Study Type
Interventional - Drug
completed
The objective of the RIVAL study was to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
Primary endpoint:
Incidence of stroke (including hemorrhagic) and systemic embolism.
Secondary endpoint:
Incidence of stroke (including hemorrhagic), systemic embolism, all death; Incidence of stroke (including hemorrhagic), systemic embolism, pulmonary embolism, acute myocardial infarction, or vascular deaths (including deaths from bleeding). All primary and secondary events are adjudicated.
RIVAL Final Results - Download PDFStudy Design
RCT parallel group
NO. of Countries
32
NO. of Sites
158
NO. of Participants
7021
Study Period
2006-2011
Sponsor
PHRI
Sanjit Jolly
Scientist
Sanjit Jolly
Scientist
Sanjit Jolly is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University. He has formal training in clinical trials with a M.Sc. in Health Research Methodology from McMaster. He was the principal investigator of the RIVAL trial, a randomized trial of 7021 patients comparing radial and femoral access for coronary intervention. He is also the principal investigator trial of the ongoing TOTAL trial, an international randomized trial (N=10,700) of thrombectomy during primary PCI.
